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Abstract
Background: TMPRSS2:ERG fusions are frequent in prostate cancer, and occur predominantly in young patients.
Several studies had proposed intratumoral heterogeneity of these fusions. This study was designed to determine
frequency and extent of ERG fusion heterogeneity in early-onset prostate cancer (EO-PCA, <50 years) and in elderly
patients.
Methods: The prostates from 63 EO-PCA and 62 elderly prostate cancer patients were thoroughly reviewed for
presence of cancer foci. All 1592 tumor-containing sections were analyzed by immunohistochemistry for ERG
expression.
Results: The prostates included in this study contained one tumor focus in 44, two tumor foci in 21, three tumor
foci in 32, four tumor foci in 15, and five or more tumor foci in 13 patients. Among 59 cancer foci with ≤3 mm, 19
(32.2 %) were homogeneously ERG positive, 39 66.1 %) were homogeneously ERG negative, and one case (1.7 %)
showed a heterogeneous ERG status. The fraction of homogeneously ERG positive cancer foci remained largely
constant (14–37 %) with increasing tumor focus diameter but the fraction of heterogeneous ERG findings
continuously increased with tumor size and reached 39 % in cancer foci larger than 22 mm. On a patient level, ERG
expression was markedly more frequent in EO-PCA than in elderly patients: 13 % of EO-PCA were homogeneously
and 62 % were heterogeneously ERG positive. In elderly patients, 3 % of cancers were homogeneously and 57 %
were heterogeneously ERG positive (p = 0.0721).
Conclusion: These data show that about 20–30 % of prostate cancer foci have early ERG fusions. ERG fusions
further occur in about 50 % of initially ERG negative cancer foci during cancer progression. The vast majority of
cancers are heterogeneous for TMPRSS2:ERG fusions on a patient level, challenging the concept of classifying
prostate cancer patients into “fusion type” and “non-fusion type” prostate cancer.
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Background
Prostate cancer is the most frequent cancer in men and
represents a major cause of cancer-related mortality and
morbidity [1]. Although the majority of these tumors be-
have in an indolent manner, a significant subset forms
highly aggressive and life threatening cancers [2]. Effect-
ive curative therapies for patients with such highly ma-
lignant cancers are still lacking. The most important
objectives of current prostate cancer research thus include
the development of improved tools for early detection of
the disease, with markers for reliably pre-therapeutic dis-
tinction between patients requiring aggressive treatment
and those who do not, as well as improved systemic treat-
ment options for patients with aggressive and metastatic
disease. It is hoped, that the rapidly increasing knowledge
of the molecular basis of prostate cancer will eventually
lead to relevant clinical applications.
Genomic rearrangements leading to gene fusions be-
tween androgen-regulated genes and ETS transcription
factors represent the most common genetic alteration in
prostate cancer. The most prevalent fusion, accounting
for more than 90 % of these rearrangements, links the
androgen receptor (AR) responsive promoter of the
TMPRSS2 serine protease to the transcription factor
ERG, either by translocation or by deletion of a 3.7
megabases (Mb) segment separating the two genes on
chromosome 21q22 [3]. Consequently, ERG becomes
androgen regulated and is massively overexpressed in
prostatic epithelium. Detecting ERG expression by immu-
nohistochemistry and visualization of ERG rearrangements
by fluorescence in situ hybridization (FISH) have proven
as equally reliable methods for detecting TMPRSS2:ERG
fusions [4, 5].
Based on the high frequency of TMPRSS2:ERG fusions
and the potentially high impact on prostate cells by
rendering ERG dependent genes androgen regulated,
attempts were made to molecularly classify prostate
cancer as “fusion-type” and “non fusion-type”. Several
studies investigated the clinical and molecular characte-
ristics of fusion type versus non-fusion type prostate
cancer. They reported that TMPRSS2:ERG fusions occur
in about 50 % of cancers and that they are unrelated to
PSA recurrence in patients treated by radical prostatec-
tomy [5] while it is possible, that fusion positive cancers
might react better to anti-androgen therapy than fusion
negative tumors [6, 7]. More recently, we had demon-
strated, that ERG fusions occur markedly more often in
young than in elderly prostate cancer patients [8].
The concept of distinguishing two clear-cut prostate
cancer categories defined by presence or absence of ETS-
gene-fusions has recently been challenged by reports
suggesting considerable heterogeneity of ERG fusions in
prostate cancer. Several studies by us [9] and others
[10–16] have demonstrated ERG interfocal heterogeneity
in 28–72 % of ERG-positive prostate cancers, and some of
these also intrafocal heterogeneity in 4–42 % of ERG-
positive tumor foci [9, 10, 12, 16, 17]. However, all these
studies had suffered from some methodological insuffi-
ciencies such as a limited number of selected tissue blocks
per patient, small numbers of patients, or were based on
tissue microarrays, a method that only involves small
tissue samples per patient [18]. To fully understand the
extent of ERG heterogeneity in prostate cancer of young
and old patients, we took a “brute force” effort and
analyzed all 1592 tumor-containing blocks of 125 prostate
cancer patients. The data reveal a very high rate of ERG
heterogeneity in prostate cancer patients.
Methods
Patients
Sixty-three prostate cancer patients were randomly se-
lected out of 273 patients that were treated by radical
prostatectomy for prostate cancer at the age of 50 or
younger (early-onset prostate cancer: EOPCA). Sixty-two
additional prostate cancers from patients older than
50 years complemented the series. None of the patients
received therapy prior to surgery. Cancers from old
patients were matched for Gleason grade and pT stage to
be comparable to the set of young patients. The patient
characteristics of both groups are given in Table 1. All
prostatectomy specimens were completely paraffin em-
bedded and processed totally according to a modified
Stanford protocol [19] as previously described [20]. In
brief, the prostates were fixed in 37 % formalin, serially
Table 1 Characteristics of the 125 analyzed prostate cancers
≤50 year >50 year
n = 63 n = 62
Age (yrs) mean ± sd 44.8 ± 2.6 75.2 ± 1.5
Prostate volume (ml) mean ± sd 28.4 ± 11.6 46.3 ± 24.5
Tumor volume (ml) mean ± sd 3.5 ± 6.9 7.0 ± 9.9
pT stage pT2 51 35
pT3a 6 18
pT3b 6 9
Gleason score ≤3 + 3 14 14
3 + 4 34 29
4 + 3 11 14
≥4 + 4 4 5
Nodal stage pN0 38 37
pN1 4 7
pNx 21 18
Resection margin status R0 47 43
R1 9 17
Rx 7 2
Number of tumor foci mean ± sd 2.4 ± 1.3 2.6 ± 1.7
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blocked at 3 mm intervals in transverse planes perpen-
dicular to the rectal surface, and embedded in paraffin.
The average number of tumor containing blocks per can-
cer was 13.2 (±7.8; range: 4–44).
Histology review
For each cancer all slides were reviewed and all cancer
containing sections were selected for further analysis by
immunohistochemistry. For each cancer, independent
tumor foci were defined according to Wise et al. [21]. In
brief, tumor areas were defined as part of a single focus
if they were within 3 mm of each other in any section or
within 4 mm on adjacent sections. This method identi-
fied 1–8 independent tumor foci in our prostate cancers
(mean: 2.5). Forty-four prostates had one tumor focus,
21 prostates had two tumor foci, 32 prostates had three
tumor foci, 15 prostates had four, seven prostates had
five tumor foci, and six prostates had 6–8 foci. For each
tumor focus, diameter and Gleason score was defined.
The size distribution of the individual tumor foci in
patients with uni- and multifocal cancers is given in
Fig. 1. In addition, individual Gleason scores were deter-
mined for the different cancer components found in the
entire prostate cancer mass.
ERG immunohistochemistry
Freshly cut sections were immunostained from each
tumor containing tissue block. The antibody ERG (clone
EPR3864, dilution 1:450, Epitomics) was used for ERG
protein detection. Slides were deparaffinized and exposed
to heat induced antigen retrieval for 5 min in an autoclave
at 121 °C at pH7.8. Bound primary antibody was visua-
lized using the EnVision™ Kit. This immunohistochemistry
(IHC) protocol was previously validated against the
TMPRSS2-ERG fusion status determined by FISH in a
series of 453 patients. ERG rearrangement had been
identified in 230 of 247 immunohistochemically ERG
positive cases (93 %) but in only 2 of 206 cases (1 %) that
were found negative by IHC [5].
Interpretation of ERG immunostaining
Tumor areas were considered ERG positive, if unequivocal
nuclear ERG staining was present. Negative or weak stain-
ing was validated by TMPRSS2-ERG FISH if admixed
lymphocytes and/or blood vessels did not show strong ERG
immunostaining. ERG immunostaining results including
the percentages of positively and negatively stained areas
were recorded for each individual cancer focus as well as
for the entire cancer mass. At the same time staining
results in PIN and non-neoplastic epithelial cells were also
recorded if seen on the selected tissue slides. If ERG immu-
nostaining was seen in tissues that did not appear to be
neoplastic based on histology, AMACR and 34BE12 immu-
nostaining was performed to either support or invalidate
our histologic interpretation of normal, PIN or cancer
glands.
Statistics
The relationship between the number of tumor foci per
patient and the focus size was estimated using the Spear-
man rank correlation analysis. Chi2 test was applied to
test the associations between patient age and ERG
heterogeneity.
Results
Association between tumor focus size and number of
foci per patient
The size distribution of the individual tumor foci in pa-
tients with uni- and multifocal cancers is given in Fig. 1.
The size of tumor foci decreased with the number of
foci per patient (Spearmen’s ρ = −0.4318, p < 0.0001).
Fig. 1 Distribution of the tumor focus size (mm) in patients in unifocal (1 focus per patient, n = 44) and multifocal cancers (≥2 foci per
patient, n = 273)
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ERG immunostaining at the patient level
The prostates of the 125 patients contained 317 indivi-
dual tumor foci measuring between 0.2 and 58 mm
(average 13.6 mm). A patient was considered heteroge-
neous for ERG immunostaining if different tumor foci had
different ERG results (interfocal heterogeneity) or if at
least one tumor focus showed a mixture of ERG positive
and ERG negative tumor cells (intrafocal heterogeneity).
On a patient level, ERG immunostaining resulted in
ten patients with homogeneous ERG positivity (8 %),
41 patients with homogeneous ERG negativity (33 %)
and 74 (59 %) patients with heterogeneous ERG findings.
Among 74 patients with heterogeneous ERG findings,
there were 25 patients (34 %) where heterogeneity was
only seen between different tumor foci (interfocal hete-
rogeneity) and 49 patients (66 %) where heterogeneity was
also (or only) within one or several tumor foci (intrafocal
heterogeneity). It is not surprising, that the frequency of
heterogeneity (on a patient basis) increased with the
number of tumor foci present in a patient’s prostate (p =
0.0238, Fig. 2).
ERG immunostaining at the tumor level
Among the 317 tumor foci identified in our cancers, 78
were homogeneously ERG positive (25 %), 176 were
homogeneously ERG negative (55 %), and 63 showed a
(intrafocal) heterogeneous ERG result (20 %). The fraction
of heterogeneous cancers increased markedly with the size
of tumor foci, while the fraction of homogeneously negative
cancers decreased accordingly (p < 0.0001, Fig. 3). Within
the 141 ERG-positive cancer foci, the majority (55.3 %) was
homogeneously ERG positive, whereas 44.7 % showed
heterogeneous staining, suggesting that ERG fusion often
occurs only as a secondary event after tumor formation. A
detectable difference in cancer morphology (i.e., gland size,
gland architecture, gland density and tumor cell mor-
phology) was not seen between ERG positive and negative
cancer foci. Representative images of ERG immunostai-
nings are given in Fig. 4.
Relationship of ERG heterogeneity with Gleason grade
To evaluate the role of ERG rearrangements with tumor
progression, we next analyzed ERG heterogeneity in
tumor foci of different Gleason grades. Intrafocal ERG
heterogeneity was found in 26 % high-grade cancers and
in 19 % of low-grade tumors, but the difference was not
statistically significant (p = 0.5694, Fig. 5).
Relationship between ERG heterogeneity and patient age
In a recent study, we had demonstrated that positive ERG
status is linked to young patient age [8]. The comparison
of 63 EO-PCA (≤50 year) with 62 PCA of elderly patients
(>50 year) showed again a difference in frequency of ERG
positivity between these groups (Fig. 6a; p = 0.0484). This
age difference became even more significant, if the ana-
lyses was done on a tumor focus level (Fig. 6b; p = 0.0003)
Fig. 2 Association between the number of tumor foci and the level of ERG heteogeneity (p = 0.0238) on a patient basis
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Fig. 3 ERG heterogeneity in prostatectomies. a Association between the tumor focus size and the level of ERG heterogeneity (p<0.0001).
b Example of a prostate with two separate tumor foci marked in red and green color
Fig. 4 Representative images of ERG immunostainings. a Negative ERG immunostaining from a homogeneous ERG negative prostate cancer. The blue
arrow indicates positive ERG immunostaining in endothelial cells as a positive control, b positive ERG immunostaining from a homogeneous ERG
positive prostate cancer, c positive ERG immunostaining (red circle) and negative ERG immunostaining (green circle) from an intrafocal heterogeneous
prostate cancer; the blue arrow indicates positive ERG immunostaining in endothelial cells as a positive control, d false heterogeneity, positive cancer
(left), false negative cancer (right), the blue arrow indicates endothelial cells also lacking ERG immunostaining (d)
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and if the analysis was limited to low grade tumor foci with
a Gleason ≤3 + 4 (Fig. 6c; p < 0.0001). An association of
ERG status with patient age was not observed within 38
high-grade (Gleason ≥4 + 3) cancer foci (Fig. 6d; p =
0.9134).
ERG expression in non-neoplastic prostate epithelia
ERG staining was frequently found in high-grade prostatic
intraepithelial neoplasia (HGPIN), where it always was
heterogeneous. In ten tumor patients, ERG-positive small
areas of non-neoplastic appearing prostatic epithelium
were also seen. Examples of such findings are shown in
Fig. 7.
Discussion
The TMPRSS2:ERG fusion represents the most common
genomic rearrangement in prostate cancer. Based on the
pivotal effect of this fusion on prostate cancer cells by
rendering ERG regulated genes androgen responsive, it
was speculated that these fusions represent a major cancer
initiating event [14]. Accordingly, it was proposed to
distinguish “fusion-type” from “non fusion-type” prostate
cancer as the two main molecular subtypes.
The data of this study suggest that pure “fusion-type”
prostate cancer, where TMPRSS2:ERG fusions constitute
a potential initiating event, may occur in not more than
one third of all prostate cancer foci. This is based on our
finding of homogeneous ERG positivity in 32 % of 59
small prostate cancer foci measuring 3 mm or less in
diameter. That this percentage remains at comparable
levels (14–36 %) irrespective of the tumor focus size is
not surprising as cancers that were initially ERG positive
are unlikely to loose TMPRSS2-ERG fusions during
tumor progression.
The considerable fraction of 44.7 % heterogeneously
ERG positive cancer foci and the continuous increase of
ERG positive areas with tumor focus size found in our
study further suggests that ERG fusion may not always be
an initiating event but can also occur later during prostate
cancer evolution. However, other studies reported less
frequent intrafocal heterogeneity. For example, Barry et al.
[11] found no unequivocal intrafocal heterogeneity in 32
multifocal prostate cancers, Furusato et al. [10] reported
three tumors with signs of intrafocal heterogeneity in 81
multifocal cancers, Gumuskaya et al. [17] identified 7 %
intrafocal heterogeneity in 44 ERG-positive tumor foci,
Young et al. [16] found 4 % intrafocal heterogeneity in 78
ERG-positive tumor foci, and Svensson et al. [12] reported
incidental intrafocal heterogeneity without specifying
exact numbers. The markedly higher fraction of intrafocal
ERG heterogeneity in unifocal cancers in our study is
obviously due to the particularly large size of the majority
Fig. 5 Association between the Gleason grade and the level of ERG heterogeneity (p = 0.5694) on a tumor focus basis
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of tumor foci (Fig. 1). It can be assumed, that the like-
lihood for subsequent ERG fusion development in initially
ERG-negative cancer foci increases with tumor size and,
therefore, over time. Alternatively, it cannot be excluded,
that a certain fraction of unifocal cancers included in our
study might represent “pseudo-unifocal tumors” resulting
from collision of two or more independent tumor foci that
cannot be distinguished histologically any more. However,
given that individual tumor foci were defined according to
generally accepted criteria in our study [21], that virtually
all tumor foci showing potential intrafocal heterogeneity
measured more than 4 mm, and that more than 80 % of
the foci identified in our study measured >4 mm, our data
suggests that either significant intrafocal heterogeneity
exists, or that foci exeeding 4 mm are typically not unifo-
cal even if they formally fulfill the criteria for unifocality.
The decreasing prevalence of completely ERG negative
foci from 70 % to about 50 % with increasing tumor
focus size suggest that subclones with TMPRSS2-ERG
fusion develop in about 30 % of initially ERG negative
cancer foci. The continuously high likelihood of prostate
epithelial cells to develop TMPRSS2-ERG fusions (and
other fusions linking ETS factors to androgen regulated
genes) can be explained by the permanently activated
androgen signaling in these cells. It has been shown that
androgen signaling induces chromatin movements resul-
ting in a close proximity of TMPRSS2 and ERG [22],
including topological DNA constraints, which are resolved
by topoisomerase 2B (TOP2B) mediated double strand
breakage (DSB) and subsequent repair. Errors in this
process result in recombinogenic TMPRSS2:ERG fusion
and eventually in clonal selection of tumor cells carrying
this alteration [23].
The large number of ERG stained sections that were
carefully evaluated in the process of this study also lead to
the identification of ten small areas of ERG-positive pros-
tate epithelial cells that do not fulfill the morphologic
criteria for cancer or high grade PIN. Although this obser-
vation may suggest that TMPRSS2-ERG fusions are not
necessarily linked to malignancy, such rare findings may
Fig. 6 Association between patient age and the level of ERG heterogeneity on the basis of all 125 patients (a) and on a tumor focus basis in
all 317 foci (b), as well as in the subsets of tumor foci with Gleason ≤3 + 4 (c) and ≥4 + 3 (d). Chi2 p-value was calculated across all groups
(ERG homogenous negative, ERG homogenous positive and ERG heterogeneous positive)
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also be due to incidental false positive ERG IHC. Two pre-
vious studies suggested an error rate of 1:10,000 for ERG
positivity based on similar rare ERG staining in benign
epithelium [10, 16].
While pure “fusion-type” prostate cancer exists in up
to 30 % on a tumor focus level, such a finding is an
absolute rarity on the patient level, where homogeneous
ERG positive cancers were only seen in ten patients
(8 %). This finding was obviously caused by the high rate
of interfocal heterogeneity in multifocal cancers. More
than 60 % of our patients had more than one cancer
focus in their prostates including 35 % with more than 3
cancer foci. While some of these cancers might have
identical precursor lesions if they develop from one high
grade PIN, it is apparent from our data, that most multi-
focal cancers represent independent “de novo” tumors
since more than 60 % of multifocal cancers had both ERG
positive and ERG negative foci. Presence of ERG positive
and ERG negative subclones in the cancers of the vast
majority of prostate cancer patients obviously challenges
the classification of prostate cancers as “fusion-type” vs.
“non-fusion type” on a patient level.
Based on our recent observation of a particularly high
frequency of ERG fusions in early-onset prostate cancer
we had hypothesized, that the development of ERG
fusions is supported by the genuinely higher serum
testosterone levels in younger than in older patients [8].
Based on the demonstrated impact of high testosterone
Fig. 7 Representative images of ERG immunostainings. (a–d) Positive ERG immunostaining in non-neoplastic appearing prostate epithelium
(a and c) with corresponding H&E staining (b and d). The blue arrow indicates normal prostate epithelium, the green arrow indicates cancer
cells. (e) Positive staining in high-grade prostatic intraepithelial neoplasia (HGPIN, red box) and negative staining in prostate cancer (green box).
(f) Heterogeneous ERG immunostaining in HGPIN (green asterisk). Red asterisk indicates invasive tumor cells
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levels facilitating ERG fusions in cell line models [22], it
appears well possible, that the same mechanism may
also apply in vivo. Our present data further validate the
recently demonstrated association of ERG fusions with
young patient age. Young patients not only have a higher
likelihood to develop homogeneously ERG positive
cancer foci (32 %) than old patients (18 %), they also
have a higher likelihood for developing ERG positive
subpopulations in initially ERG negative cancers.
It is a unique feature of our study, that a large series of
cancers was assessed for heterogeneity by analyzing every
individual cancer containing tissue block. The analysis
involved a biomarker earlier considered a major classifier
for prostate cancer. The very high rate of heterogeneity
(89 %) found for “ERG positive” cancers highlights the
importance of cancer heterogeneity. At times when drugs
are increasingly administered based on the results of
molecular analyses, and where drugs are being developed
to target molecular features, it is of utmost importance to
fully understand the impact of heterogeneity for poten-
tially relevant molecular properties. It may be just by
chance that Her2 - the most successful membranous drug
target - is homogeneously expressed in >90 % of breast
cancers, the main cancer type for anti-Her2 drugs. It is
remarkable, that – at least in the literature - thorough
heterogeneity analyses are still lacking for many drug
targets under development.
Conclusions
In summary, these data show, that homogeneous ERG
positivity is very rare in prostate cancer, especially in elderly
patients. However, development of subpopulations with
ERG fusions may be a much more frequent event in ERG
negative cancer foci as previously believed.
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